BioAdvance News Portfolio News Venatorx Pharmaceuticals

Venatorx Pharmaceuticals Expands Anti-Infective Portfolio with HBV Candidate

By WebmasterMarch 10, 2021November 1st, 2024No Comments

Venatorx Pharmaceuticals Expands Anti-Infective Portfolio with HBV Candidate

VNRX-9945 Selected as 3rd Generation Hepatitis B Virus Orally Bioavailable CpAM; Clinical Trial Application and Phase 1 Planned for Second Quarter 2021

See more here

Previous PostAnnovis Bio Signs GMP Manufacturing Agreement to Support Planned Late-Stage Studies
Next PostAnnovis Bio Receives Japanese Patent for the Treatment of Acute Brain or Nerve Injury

Venatorx Pharmaceuticals Expands Anti-Infective Portfolio with HBV Candidate

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostAnnovis Bio Signs GMP Manufacturing Agreement to Support Planned Late-Stage Studies

Next PostAnnovis Bio Receives Japanese Patent for the Treatment of Acute Brain or Nerve Injury